Alendronate: a new bisphosphonate for the treatment of osteoporosis
Keen, R.W.; Spector, T.D.
British Journal of Clinical Practice 50(4): 211-217
1996
ISSN/ISBN: 0007-0947 PMID: 8759568 Document Number: 463643
Alendronate is a drug with considerable potential. It is likely to work best in elderly patients with moderate to severe osteoporosis. Long-term studies and comparison with other therapeutic agents are needed before its exact role is established.
Document emailed within 1 workday
Related Documents
Kobayashi, S.; Shiraki, M.; Takaoka, K. 2004: Treatment of osteoporosis combined with a bisphosphonate and vitamin D3 Nihon Rinsho. Japanese Journal of Clinical Medicine 62(Suppl 2): 461-465Wang, X.; Yang, Z.; Yu, S. 2001: The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model Zhonghua Kou Qiang Yi Xue Za Zhi 36(3): 193-196
Miki, T. 2017: Efficacy and safety of long-term bisphosphonate treatment for osteoporosis Clinical Calcium 27(2): 239-246
Rossini, M.; Di Munno, O.; Gatti, D.; Giannini, S.; Minisola, S.; Varenna, M.; Adami, S. 2011: Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience Clinical and Experimental Rheumatology 29(4): 728-735
Jiang, Y.; Li, M.; Xia, W.; Xing, X.; Yu, W.; Tian, J.; Meng, X.; Zhou, X. 2002: Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal Zhonghua Yi Xue Za Zhi 82(18): 1254-1256
Rugpolmuang, L.; Waikakul, S. 2015: Effect of a Short-Term Treatment with Once-A-Week Medication of Alendronate 70 Mg on Bone Turnover Markers in Postmenopausal Women with Osteoporosis Journal of the Medical Association of Thailand 98(Suppl 8): S70-S75
Urade, M. 2009: New development in bisphosphonate treatment. Bisphosphonate therapy and osteonecrosis of the jaws Clinical Calcium 19(1): 100-108
Kristiansen, I.S.; Falch, J.A.; Andersen, L.; Aursnes, I. 1997: Use of alendronate in osteoporosis--is it cost-effective? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 117(18): 2619-2622
Minisola, S.; Scillitani, A.; Romagnoli, E. 2006: Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis New England Journal of Medicine 355(20): 2156-2157; Author Reply 2157
Dursun, N.; Dursun, E.; Yalçin, S. 2001: Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis International Journal of Clinical Practice 55(8): 505-509
Wynn, R.L. 2007: Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw? General Dentistry 55(6): 495-498
Papapoulos, S.E. 2003: Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis International Journal of Clinical Practice 57(5): 417-422
Buffo, L.; Rossini, M.; Buoncristiano, A.; Girardello, S.; Zamberlan, N.; Diani, F.; Adami, S. 1996: Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate Minerva Ginecologica 48(6): 263-272
Wang, Q-hong.; Wu, H-xiang.; Huang, Y-lu.; Xue, J.; Yang, X-yan.; Zhu, L.; Wen, L-hong. 2008: Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases Zhonghua Yi Xue Za Zhi 88(27): 1888-1891
Wang, C.; He, J.-w.; Qin, Y.-j.; Zhang, H.; Hu, W.-w.; Liu, Y.-j.; Zhang, Z.-l. 2009: Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis Zhonghua Yi Xue Za Zhi 89(42): 2958-2962
Koval, P.G.; Easterling, L.; Pettus, D.; Mackler, L.; Gottschall, A.B. 2005: Clinical inquiries. how should a DEXA scan be used to evaluate bisphosphonate therapy for osteoporosis? Journal of Family Practice 54(1): 65; 69-71
Ijiri, S. 2008: Patient's preference for the daily and weekly bisphosphonate--evaluation from questionnaire of osteoporosis patients Nihon Rinsho. Japanese Journal of Clinical Medicine 66(1): 205-211
Grana, J.; Mahia, I.V.; Meizoso, M.-O.S.; Vazquez, T. 2008: Multiple osteonecrosis of the jaw, oral bisphosphonate therapy and refractory rheumatoid arthritis (Pathological fracture associated with ONJ and BP use for osteoporosis) Clinical and Experimental Rheumatology 26(2): 384-385
Arboleya, L.R.; Morales, A.; Fiter, J. 2000: Effect of alendronate on bone mineral density and incidence of fractures in postmenopausal women with osteoporosis. A meta-analysis of published studies Medicina Clinica 114 Suppl. 2: 79-84
Harada, A. 2009: Alendronate for treatment of osteoporoses Nihon Rinsho. Japanese Journal of Clinical Medicine 67(5): 943-947